

Release of Securities from Voluntary Escrow

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a commercial stage microbiome company, advises in accordance with ASX Listing Rule 3.10A that the following unlisted options will be released from voluntary escrow on 5 April 2023.

No. of Options	Class of Options
7,850,000	Unlisted Options exercisable at \$0.18 on or before 15 October 2023

- Ends -

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.